NASDAQ:TRVN Trevena (TRVN) Stock Price, News & Analysis $0.01 0.00 (0.00%) As of 09/23/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC Filings About Trevena Stock (NASDAQ:TRVN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Trevena alerts:Sign Up Key Stats Today's Range$0.0112▼$0.011250-Day Range N/A52-Week Range$0.00▼$1.50Volume44 shsAverage Volume726 shsMarket Capitalization$10.74 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Trevena, Inc. is a biopharmaceutical company focused on developing medicines that target G protein-coupled receptors (GPCRs), a class of proteins involved in pain, neurological conditions and other diseases. The company was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania. Trevena’s best-known product is OLINVYK (oliceridine) injection, an intravenous opioid analgesic approved by the U.S. Food and Drug Administration in 2020 for the management of acute pain severe enough to require an intravenous opioid analgesic in adults. OLINVYK was designed as a selective mu-opioid receptor agonist and was developed to provide pain relief while addressing certain limitations associated with traditional opioid therapies. The company has also conducted research on additional therapies for pain and central nervous system disorders, including investigational oral and non-opioid treatments. Trevena’s primary commercial and regulatory activities have been focused on the United States, while its development programs and partnerships have supported efforts to expand the potential reach of its drug candidates. Because the company’s operations and product-development activities have changed over time, investors should consult its latest public filings for current information about its leadership, pipeline and commercial status.AI Generated. May Contain Errors. Read More Receive TRVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TRVN Stock News HeadlinesTrevena (NASDAQ:TRVN) Share Price Passes Below 200-Day Moving Average - Should You Sell?September 18, 2026 | americanbankingnews.comTrevena Inc.May 27, 2026 | marketwatch.comMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 people worldwide. His system has flagged a handful of stocks worth watching ahead of September 30th. See which stocks his AI research platform is flagging right now.September 24 at 1:00 AM | TradeSmith (Ad)Trevena Restructures China Royalty Rights to Exit DebtJanuary 14, 2026 | tipranks.comSoftball: Conrad Weiser’s Alex Trevena earns statewide player of the year award; 5 other Berks players honoredJuly 8, 2025 | msn.comTrevena, Inc. (TRVN) - Yahoo FinanceJune 29, 2025 | finance.yahoo.comTrevena Enters Securities Exchange Agreement with InvestorMay 15, 2025 | tipranks.comVanessa Hudgens and Oliver Trevena Appear at Expo West for CaliwaterMarch 9, 2025 | msn.comSee More Headlines TRVN Stock Analysis - Frequently Asked Questions How have TRVN shares performed this year? Trevena's stock was trading at $0.0120 on January 1st, 2026. Since then, TRVN shares have decreased by 6.7% and is now trading at $0.0112. How were Trevena's earnings last quarter? Trevena, Inc. (NASDAQ:TRVN) announced its quarterly earnings data on Thursday, August, 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($9.25) by $9.02. The biopharmaceutical company had revenue of $0.33 million for the quarter. When did Trevena's stock split? Shares of Trevena reverse split on the morning of Tuesday, August 13th 2024.The 1-25 reverse split was announced on Thursday, August 8th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Trevena? Shares of TRVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Trevena own? Based on aggregate information from My MarketBeat watchlists, some other companies that Trevena investors own include Novavax (NVAX), Conatus Pharmaceuticals (CNAT), Sorrento Therapeutics (SRNE), NIO (NIO), TherapeuticsMD (TXMD), SCYNEXIS (SCYX). Company Calendar Last Earnings8/08/2024Today9/24/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:TRVN CIK1429560 Webwww.trevena.com Phone(610) 354-8840FaxN/AEmployees23Year Founded2008Profitability EPS (Trailing Twelve Months)($47.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$40.29 million Net MarginsN/A Pretax Margin-6,222.30% Return on EquityN/A Return on Assets-119.55% Debt Debt-to-Equity RatioN/A Current Ratio2.42 Quick Ratio2.42 Sales & Book Value Annual Sales$443 thousand Price / Sales0.02 Cash FlowN/A Price / Cash FlowN/A Book Value($11.07) per share Price / Book0.00Miscellaneous Outstanding Shares959,000Free Float841,000Market Cap$10.74 thousand OptionableNo Data Beta-0.55 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:TRVN) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevena, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevena With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
